Majumder Md Anwarul Azim, Singh Keerti, Johnson W M S, Rajasundaram Archana, Gupta Subir, Gaur Uma, Kumar Santosh, Chatterjee Madhuri, Fazle Rabbi Ahbab Mohammad, Sangishetti Vijay Prasad, Rahman Sayeeda, Campbell Michael H, Harewood Heather, Bharatha Ambadasu, Krishnamurthy Kandamaran, Kabir Russell, Parsa Ali Davod, Mohammmad Shegufta, Haque Mainul, Razzaque Mohammed S
Public Health Foundation of Bangladesh, Dhaka, Bangladesh.
Faculty of Medical Sciences, The University of the West Indies, Bridgetown, Barbados.
J Multidiscip Healthc. 2023 Jan 19;16:161-174. doi: 10.2147/JMDH.S390364. eCollection 2023.
Efficacy and safety are fundamental for the development of successful COVID-19 vaccines. Vaccine-associated side effects influence vaccine hesitancy. This study investigated the prevalence, severity, and onset of side effects following the first dose of COVID-19 vaccines among physicians and dentists working in various healthcare settings across India.
A cross-sectional survey collected self-report data from April to June 2021 on side effects following the first dose of the vaccine. An online validated questionnaire using the Google Docs platform was circulated via email and social media platforms.
More than 40% of participants experienced at least one side effect after the first dose of vaccination; the most common were mild and resolved within three days after vaccination. More than 91% of respondents received the Covishield (AstraZeneca) vaccine; the most prevalent adverse effects were soreness of the injected arm (78.9%), tiredness (71.1%), and fever (54.9%). Logistic regression showed that women were almost 60% less likely to report side effects.
Findings supported the safety of the first dose of the COVID-19 vaccine based on relatively few self-limiting side effects, mainly soreness of the injected arm and tiredness. Further research is needed to determine the long-term safety of COVID-19 vaccines, especially after booster doses.
有效性和安全性是成功研发新冠疫苗的基础。疫苗相关的副作用会影响疫苗接种的犹豫态度。本研究调查了印度各地不同医疗机构工作的医生和牙医接种第一剂新冠疫苗后副作用的发生率、严重程度和发作情况。
一项横断面调查收集了2021年4月至6月期间关于接种第一剂疫苗后副作用的自我报告数据。使用谷歌文档平台的在线有效问卷通过电子邮件和社交媒体平台分发。
超过40%的参与者在接种第一剂疫苗后至少出现一种副作用；最常见的是轻度副作用，且在接种疫苗后三天内缓解。超过91%的受访者接种了Covishield（阿斯利康）疫苗；最常见的不良反应是注射部位疼痛（78.9%）、疲劳（71.1%）和发热（54.9%）。逻辑回归显示，女性报告副作用的可能性降低近60%。
研究结果支持了第一剂新冠疫苗的安全性，其副作用相对较少且具有自限性，主要是注射部位疼痛和疲劳。需要进一步研究以确定新冠疫苗的长期安全性，尤其是加强针后的安全性。
